Oxford Biomedica PLC — Director's Dealing 2026

May 19, 2026

National Storage Mechanism | Additional information

RNS Number : 9106E

Oxford Biomedica PLC

19 May 2026

PDMR Dealing

Oxford, UK - 19 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kathleen Miller has exercised 4,486 Restricted Share Units ("RSU") options granted under the 2024 Long Term Incentive Plan ("2024 LTIP Plan") at an exercise price of £nil on 18 May 2026 and disposed of 1,578 ordinary shares at an average price of £6.091 per share on 18 May 2026.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Is this a PDMR or PCA submission

Submission for PDMR

b)

Name of natural person

Kathleen Miller

c)

Legal person

2.

Reason for the notification

a)

Position/status

Head of Human Resources (and acting Interim Site Head, Bedford Operations)

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Full name of the entity

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

18-May-2026

b)

Description of the financial instrument

Share

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of the transaction

Exercise of 4,486 RSUs under 2024 LTIP Plan

e)

Place of the transaction

Outside the trading venue

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
0.00	4,486

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

4,486

£0.00

£0.00

1.

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Is this a PDMR or PCA submission

Submission for PDMR

b)

Name of natural person

Kathleen Miller

c)

Legal person

2.

Reason for the notification

a)

Position/status

Head of Human Resources (and acting Interim Site Head, Bedford Operations)

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Full name of the entity

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Date of the transaction

18-May-2026

b)

Description of the financial instrument

Share

c)

Identification code

ISIN: GB00BDFBVT43

d)

Nature of the transaction

Sale of 1,578 ordinary shares

e)

Place of the transaction

London Stock Exchange, Main Market (XLON)

f)

Currency

GBP - British pound

g)

Price(s) and volumes(s)

Price(s)	Volume(s)
£6.091	1,578

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

1,578

£6.091

£9,611.60

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: [email protected]

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHAKCBPFBKKQPD